The Little Princess Trust (LPT) has announced 10 new research projects that will improve outcomes for children with cancer, awarded in partnership with Children’s Cancer and Leukaemia Group (CCLG).
The LPT is a key childhood cancer research funder and works in collaboration with CCLG, using its research expertise and professional contacts to assess and manage their projects. The two organisations’ shared commitment ensures the selection of only the most impactful research projects and the best researchers.
In the LPT's final round of project grants in 2023, 10 childhood cancer research projects were funded, contributing to the 30 projects supported through the CCLG Research Funding Network last year.
CCLG Chief Executive Ashley Ball-Gamble said:
Our partnership with The Little Princess Trust is a beacon of hope for children with cancer. We are delighted to be working together on nearly 130 research projects and are proud to be facilitating The Little Princess Trust’s substantial investment in childhood cancer research.
The new projects span seven types of cancer, promising insights into how cancers develop and giving hope for kinder and more effective treatments.
Phil Brace, CEO of the LPT said: "In our ongoing partnership with CCLG, The Little Princess Trust is proud to announce the funding of 10 exciting new research projects, spanning various childhood cancers.
“This partnership has been a key part of our strategy since we first started funding research in 2016, and we are proud to have invested almost £23 million in childhood cancer research since then through the partnership. Together, we are advancing childhood cancer research with innovative and targeted approaches.”
You can read more about the new projects below.
Brain and spinal tumours:
- Investigating the potential of interfering with glutamine addiction to better treat MYC-driven medulloblastoma - Professor Daniel Tennant
- Tumour-collagen targeted IL-12 cancer immunotherapy for paediatric high-grade glioma - Dr Jun Ishihara
Leukaemia:
- Identifying and modelling the origin of therapy-related childhood leukaemia - Dr Alex Thompson
- Identification of therapeutic targets in MNX1-rearranged infant acute myeloid leukaemia - Dr Cristina Pina
- Targeting beta:catenin:RNA/RBP interactions in paediatric acute myeloid leukaemia - Dr Rhys Morgan
Wilms tumour:
- A potent synergistic and selective combination methyltransferase therapy for poor prognosis Wilms' tumour - Professor Karim Malik
- Molecular characterisation of cancer stem cells and their microenvironment in Wilms tumour in the quest for new cancer treatment strategies in high-risk patients - Dr Bettina Wilm
Neuroblastoma:
- Deciphering the role of chromosomal copy number variants in paediatric tumour initiation - Dr Anestis Tsakiridis
- Investigating the utility of histone post-translational modifications and the proteins that regulate them as therapeutic targets and biomarkers for high-risk neuroblastoma - Professor Suzanne Turner and Dr Perla Pucci
- Tri-specific GD2/B7-H3 T cell engaging antibodies in neuroblastoma - Dr Juliet Gray